<p><strong><u>Release Date</u></strong> <br>
  December  5, 2014<br>
  <br>
  <strong><u>Expiration Date</u></strong> <br>
  December  5, 2015<br>
  <strong><u><br>Faculty</u></strong>
    <br>
    Fausto  Castagnetti, MD, PhD<br>
Bologna University School of Medicine<br>
Bologna, Italy</p>
<p>Jorge  Cortes, MD<br>
  The University of Texas <br>
  MD Anderson Cancer Center<br>
Houston, Texas, United States</p>
<p>Francesca  Gay, MD<br>
  University of Torino<br>
Torino, Italy</p>
<p>Jonathan  Kaufman, MD<br>
  Winship Cancer Institute<br>
  Emory University<br>
Atlanta, Georgia, United States</p>
<p>Jean-Jacques  Kiladjian, MD, PhD<br>
  Hôpital Saint-Louis &amp; Université Paris Diderot<br>
Paris, France</p>
<p>Nicolaus  Kröger, MD<br>
  University Medical Center Hamburg-Eppendorf<br>
Hamburg, Germany</p>
<p>Shaji Kumar,  MD<br>
  Mayo Clinic<br>
Rochester, Minnesota, United States</p>
<p>Jeffrey  Lipton, MD, PhD, FRCPC<br>
  Princess Margaret Cancer Centre<br>
  University of Toronto<br>
Toronto, Ontario, Canada</p>
<p>Ruben Mesa,  MD<br>
  Mayo Clinic Cancer Center<br>
Scottsdale, Arizona, United States</p>
<p>Dietger  Niederwieser, MD <br>
  University of Leipzig<br>
Leipzig, Germany</p>
<p>Susan  O&rsquo;Brien, MD<br>
  The University of Texas <br>
  MD Anderson Cancer Center<br>
Houston, Texas, United States</p>
<p>Antonio  Palumbo, MD<br>
  University of Torino<br>
Torino, Italy</p>
<p>Jesus San  Miguel, MD, PhD<br>
  Universidad de Navarra<br>
Pamplona, Spain</p>
<p>Jatin Shah,  MD<br>
  The University of Texas<br>
  MD Anderson Cancer Center<br>
Houston, Texas, United States</p>
<p>Jeff  Sharman, MD<br>
  Willamette Valley Cancer Institute/US Oncology Research<br>
Springfield, Oregon, United States</p>
<p>A. Keith  Stewart, MD<br>
  Mayo Clinic<br>
Scottsdale, Arizona, United States</p>
<p>Alessandro  Vannucchi, MD<br>
  University of Florence<br>
Florence, Italy</p>
<p>Ravi Vij,  MBBS, MD<br>
  Washington University School of Medicine<br>
  Saint Louis, Missouri, United States</p>
<p><strong>
<u class="bullets">Learning Objectives</u></strong><br>
After successful completion of this  educational activity, participants should be able to:</p>
<ul>
  <li>Evaluate recent findings from studies  investigating biomarkers and molecular features of hematologic malignancies and  disorders</li>
  <li>Apply emerging data from clinical  trials evaluating novel agents and treatment  approaches for hematologic malignancies and disorders</li>
  <li>Identify  appropriate clinical trials and refer eligible patients with hematologic  malignancies and disorders for enrollment to expand their treatment options</li>
</ul><br>

<p><strong><u>
  Sponsorship </u></strong><br>
  This activity is sponsored by prIME Oncology. <br>
  <strong><u><br>
  Support </u></strong><br>
  Support for this educational activity is provided by Onyx  Pharmaceuticals, Inc. and Pharmacyclics.<br>
  <strong><u><br>
  Target Audience </u></strong><br>
  This  educational activity is specifically designed for practicing hematologists;  medical, surgical, and radiation oncologists; and other healthcare  professionals interested in and/or involved in the treatment of patients with  cancer in the United States.<br>
  <strong><u><br>
  Continuing Medical Education</u></strong><br>
prIME Oncology is accredited by the  Accreditation Council for Continuing Medical Education (ACCME®) to provide  continuing medical education for physicians.</p>
prIME Oncology designates  this enduring activity for a maximum of&nbsp;X.XX<em><em>AMA PRA Category 1 Credits</em></em><strong><em>™<em><em>.</em></em></em></strong>Physicians should claim only credit commensurate with the extent  of their participation in the activity.
<br>
<strong><u><br>
  Method of Participation</u></strong><br>
  <p>There are no fees for participating in and  receiving CME credit for this activity. In order to receive credit,  participants must successfully complete the online post test and activity  evaluation. Your participation in this CME activity will be recorded in prIME  Oncology's database. However, upon request, your CME credit certificate will be  emailed to you. Technical requirements may be found under the <a href="http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx">Terms of Use</a>. <br>
    <br>
    A link to the posttest is available on the video player pages.</p>
In order to claim credit  for this activity, a score of XX%  or higher is required.<br>
<strong><u><br>
Disclosure of Conflicts of Interest</u></strong><br>
prIME  Oncology assesses conflicts of interest with its instructors, planners,  managers, and other individuals who are in a position to control the content of  CME activities.&nbsp;All relevant conflicts of interest that are identified are  thoroughly vetted by prIME Oncology for fairness, balance, and scientific  objectivity of data, as well as patient care recommendations. prIME Oncology is  committed to providing its learners with high-quality CME activities and  related materials that promote improvements or quality in healthcare and not a  specific proprietary business interest of a commercial entity.<br>
<strong><br>
Faculty Disclosures</strong><br>
<p>The faculty reported the following financial  relationships or relationships to products or devices they or their  spouses/life partners have with commercial interests related to the content of  this CME activity:<br>
  <br>
  Dr Castagnetti has _______. He has agreed to  disclose any unlabeled/unapproved uses of drugs or products referenced in his  presentation.<br>
  <br>
  Dr Cortes has _______. He has agreed to  disclose any unlabeled/unapproved uses of drugs or products referenced in his  presentation. <br>
  <br>
  Dr Gay has _______. She has agreed to  disclose any unlabeled/unapproved uses of drugs or products referenced in her  presentation. <br>
  <br>
  Dr Kaufman has _______. He has agreed to  disclose any unlabeled/unapproved uses of drugs or products referenced in his  presentation.<br>
  <br>
  Dr Kiladjian has _______. He has agreed to  disclose any unlabeled/unapproved uses of drugs or products referenced in his  presentation. <br>
  <br>
  Dr Kröger has _______. He has agreed to  disclose any unlabeled/unapproved uses of drugs or products referenced in his  presentation. <br>
  <br>
  Dr Kumar has _______. He has agreed to  disclose any unlabeled/unapproved uses of drugs or products referenced in his  presentation.<br>
  <br>
  Dr Lipton has _______. He has agreed to  disclose any unlabeled/unapproved uses of drugs or products referenced in his  presentation. <br>
  <br>
  Dr Mesa has _______. He has agreed to  disclose any unlabeled/unapproved uses of drugs or products referenced in his  presentation. <br>
  <br>
  Dr Niederwieser has _______. He has agreed to  disclose any unlabeled/unapproved uses of drugs or products referenced in his  presentation. <br>
  <br>
  Dr O&rsquo;Brien has _______. She has agreed to  disclose any unlabeled/unapproved uses of drugs or products referenced in her  presentation. <br>
  <br>
  Dr Palumbo has _______. He has agreed to  disclose any unlabeled/unapproved uses of drugs or products referenced in his  presentation.<br>
  <br>
  Dr San Miguel has _______. He has agreed to  disclose any unlabeled/unapproved uses of drugs or products referenced in his  presentation.<br>
  <br>
  Dr Shah has _______. He has agreed to  disclose any unlabeled/unapproved uses of drugs or products referenced in his  presentation. <br>
  <br>
  Dr Sharman has _______. He has agreed to  disclose any unlabeled/unapproved uses of drugs or products referenced in his  presentation.<br>
  <br>
  Dr Vannucchi has _______. He has agreed to  disclose any unlabeled/unapproved uses of drugs or products referenced in his  presentation. <br>
  <br>
  Dr Vij has _______. He has agreed to disclose  any unlabeled/unapproved uses of drugs or products referenced in his  presentation. <br>
  <br>
The  employees of prIME Oncology have disclosed:</p>
<ul type="disc">
  <li>Janice Galleshaw, MD (medical content       reviewer/planner) – no relevant financial relationships </li>
  <li>Chelsey Goins, PhD (clinical content reviewer/planner) – no       relevant financial relationships </li>
  <li>Briana Betz, PhD (clinical content reviewer/planner) – no       relevant financial relationships </li>
  <li>Trudy Stoddert, ELS       (editorial content reviewer) – no relevant financial relationships </li>
</ul>
<strong><u><br>
  Disclosure Regarding Unlabeled Use</u></strong><br>
  This activity may contain discussion of  published and/or investigational uses of agents that are not indicated by the  US Food and Drug Administration or European Medicines Agency. Please refer to  the official prescribing information for each product discussed for discussions  of approved indications, contraindications, and warnings.
  <strong><u><br>
  <br>
  Disclaimer</u></strong><br>
  Participants  have an implied responsibility to use the newly acquired information to enhance  patient outcomes and their own professional development. The information  presented in this activity is not meant to serve as a guideline for patient  management. Any procedures, medications, or other courses of diagnosis or  treatment discussed or suggested in this activity should not be used by  clinicians without evaluation of their patients' conditions and possible  contraindications or dangers in use, review of any applicable manufacturer's  product information, and comparison with recommendations of other authorities.